Upload
tejano
View
18
Download
0
Embed Size (px)
DESCRIPTION
Final Results of a Randomized Phase II Study of Perifosine in Combination with Capecitabine (P-CAP) vs. Placebo Plus Capecitabine (CAP) in Patients with 2 nd or 3 rd Line mCRC Abstract # 3531. D Richards 1 , J Nemunaitis 2 , S Vukelja 1 , C Hagenstad 3 , L Campos 4 , J Letzer 5 , - PowerPoint PPT Presentation
Citation preview
Final Results of a Randomized Phase II Study of Perifosine in Combination
with Capecitabine (P-CAP) vs. Placebo Plus Capecitabine (CAP) in Patients with 2nd or 3rd Line mCRC
Abstract # 3531
D Richards1, J Nemunaitis2, S Vukelja1, C Hagenstad3, L Campos4, J Letzer5,R Hermann6, P Sportelli7, L Gardner7 and J Bendell8
(1) Texas Oncology, Tyler, TX, (2) Mary Crowley Cancer Research Center, Dallas, TX,(3) Suburban Hematology/Oncology, Lawrenceville, GA, (4) Oncology Consultants, Houston, TX,
(5) Kalamazoo Hematology Oncology, Kalamazoo, MI, (6) Northwest Georgia Oncology, Marietta, GA,(7) Keryx Biopharmaceuticals, Inc., NY, NY, (8) Sarah Cannon Research Institute, Nashville, TN
Perifosine Oral alkylphospholipid
Inhibition of multiple signal transduction pathways– AKT inhibition– NF-B inhibition– Activation of apoptotic pathway via JNK
Selective tumor cell accumulation and potential disruption of membrane asymmetry
Potential Mechanisms of Action of Perifosine + Capecitabine
NF-B Inhibition– Fluorouracil resistance associated with upregulation of NF-B1
– Inhibition of NF-B pathway (proteasome inhibitors, mTOR inhibitors) augments fluorouracil anti-tumor effect2
– Perifosine shown to inhibit NF-B nuclear translocation and pathway activation3
Anti-angiogenic effects– Downstream inhibition of VEGF receptor signaling pathway– Anti-VEGF therapy potentially augments chemotherapy
1. Voboril, R., et al., Inhibition of NF-kappa B augments sensitivity to 5-fluorouracil/folinic acid in colon cancer. J Surg Res, 2004. 120(2)
2. Nakanishi, C. and M. Toi, Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer, 2005. 5(4)
3. Leleu, X., et al., Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood, 2008. 111(10)
Treatment Plan / Schema
Cycle = 21 Days
Primary Objective:– To compare time to progression (TTP) of P-CAP vs. CAP as 2nd or
3rd line Rx
Secondary Objective: – To compare overall response rate (CR + PR) and overall survival– To evaluate the safety of P-CAP vs. CAP
Patients with 2nd or 3rd line mCRC
No prior Rx with CAP in metastatic setting
Prior Rx with 5-FU or 5-FU based regimen
Patient Demographics
DemographicP-CAP (n = 20)
CAP(n = 18)
All Patients(n = 38)
Median Age 65 (range 32 – 83) 65 (range 43 – 83) 65 (range 32-83)
Male / Female 14 / 6 9 / 9 23 / 15
Median Prior Rx 2 (range 1-4) 2 (range 2-5) 2 (range 1-5)
ECOG PS: 0/1 6 / 14 5 / 13 11 / 27
Refractory to prior 5 – FU Rx
14 70 %
1372%
2771%
38 Patients Enrolled
Prior Rx by Arm
PRIOR RxP-CAP
( n = 20)CAP
(n = 18)All Patients
N=38
FOLFIRI 18 (90%) 16 (89%) 34 (89%)
FOLFOX 15 (75%) 13 (72%) 28 (74%)
FOLFIRI & FOLFOX
13 (65%) 12 (67%) 25 (66%)
Bevacizumab 15 (75%) 15 (83%) 30 (79%)
EGFR Antibody 9 (45%) 10 (56%) 19 (50%)
89% of patients were third line or greater
Results: Safety ( n = 38 )
Most Common Grade 1 & 2 Adverse Events
Adverse EventP-CAP (20 pts)
n (%)CAP (18 pts)
n (%)
Diarrhea 15 (75%) 5 (28%)
Fatigue 10 (50%) 6 (33%)
Nausea 9 (45%) 5 (28%)
Musculoskeletal Pain 6 (30%) 3 (17%)
Hand & Foot 5 (25%) 4 (22%)
Mucositis 5 (25%) 1 (6%)
Anorexia 5 (25%) 2 (11%)
Anemia 5 (25%) 3 (17%)
Grade 3 & 4 Adverse Events: > 10%
Adverse EventP-CAP (n=20)
CAP(n=18)
Hand and Foot 6 (30%) 0%
Anemia 3 (15%) 0%
Abdominal Pain 1 (5%) 2 (11%)
Fatigue 0% 2 (11%)
Bowel Obstruction 0% 2 (11%)
Median time to onset of Grade 3 / 4 Hand-Foot Syndrome for perifosine arm: 19 wks
Median time to onset of Hand-Foot Syndrome for CAP: 11 weeks
Results: Safety ( n = 38 )
Results: Response
All Evaluable: n = 35
Group nCR
N (%)PR
N (%)Duration of Response
(months)SD > 12 Weeks
N (%)SD or >*
N (%)
P-CAP 20 1 (5%) 3 (15%)CR: 34
11 (55%) 15 (75%)PR: 21, 19, 11
CAP 15 0 1 (7%) PR: 7 5 (33%) 6 (40%)
*p = 0.036
5-FU Refractory: n = 25
Group nPR
N (%)Duration of Response
(months)SD > 12 Weeks
N (%)SD or >*
N (%)
P-CAP 14 1 (7%) 19 months 8 (57%) 9 (64%)
CAP 11 0 - 3 (27%) 3 (27%)
*p = 0.066
35 / 38 Patients evaluable for efficacy 3 placebo patients not evaluable: 2 off for toxicity at d 14, 46; 1 off at d 4 for other disease
Median Time to Progression (TTP)
5-FU REFRACTORY PATIENTS
Median TTP: P-CAP:18 weeks [95% CI (12, 36)]
Median TTP: CAP: 10 weeks [95% CI (6.6, 11)]
p-value = 0.0004
Hazard ratio: 0.186(0.066, 0.521)
ALL EVALUABLE PATIENTS
Median TTP: P-CAP: 28 weeks [95% CI (12, 48)]
Median TTP: CAP: 11 weeks [95% CI (9, 15.9)]
p-value = 0.0012
Hazard ratio: 0.284(0.127, 0.636)
Median Overall Survival (OS)
5-FU REFRACTORY PATIENTS
Median OS: P-CAP:15.1 mos [95% CI (7.3, 22.3)]
Median OS: CAP: 6.6 mos [95% CI (4.7, 11.7)]
p-value = 0.0112
Hazard ratio: 0.313(0.122, 0.802)
ALL EVALUABLE PATIENTS
Median OS: P-CAP: 17.7 mos [95% CI (8.5, 24.6)]
Median OS: CAP: 10.9 mos [95% CI (5, 16.9)]
p-value = 0.0161
Hazard ratio: 0.410(0.193, 0.868)
Randomized Phase II Conclusions Although a small study, perifosine + capecitabine
(P-CAP) appears to improve TTP, ORR and OS compared to placebo + capecitabine (CAP)
These results are also seen in the subset of patients with 5-FU refractory disease
P-CAP was well-tolerated compared to CAP alone Increase in grade 3/4 hand-foot syndrome, anemia
A randomized ph III study comparing P-CAP to CAP in patients with refractory mCRC has been initiated (X-PECT Trial)
X-PECT TrialRANDOMIZED, DOUBLE-BLIND, PHASE III TRIAL OF PERIFOSINE + CAPECITABINE
(P-CAP) VERSUS PLACEBO + CAPECITABINE (CAP) IN PATIENTS WITH
REFRACTORY METASTATIC COLORECTAL CANCER
Opened April 2010
Treatment / Schema
Cycle = 21 Days
Patients with refractory mCRC
No prior Rx with CAP in metastatic setting
Randomized 1:1, Double-blind N = ~430 patients RECIST v 1.1 CTCAE v 4.0
Primary Endpoint: Overall Survival
Secondary Endpoints: PFS, ORR, Safety
*Phase I study perifosine + capecitabine with capecitabine at 1000 mg/m2 PO
BID days 1 – 14 showed safety and tolerability of combination
(ASCO 2010 Abstract # 51462)